Strategic partnerships OraSure has recently integrated with Roche to enhance patient-centric diagnostics using Colli-Pee Dx urine collection with NucleoPrecision technology and Roche’s high-throughput testing capabilities, signaling a strong opportunity to cross-sell integrated diagnostic workflows and expanded distribution channels.

Board and leadership Continued governance changes with new independent directors and executive leadership shifts indicate potential for refreshed strategic initiatives and enterprise-wide initiatives that can be paired with enterprise sales of diagnostic and sample collection solutions.

Healthcare reach Global sales footprint to clinical labs, hospitals, clinics, public health and community organizations, researchers, and government bodies creates multiple access points for upselling expanded test kits, sample collection devices, and stabilization solutions across care settings.

Technology leverage The tech stack including cloud data pipelines and digital marketing tools suggests opportunities to offer data integration services, analytics, and remote monitoring around diagnostic workflows to improve utilization and outcomes.

Growth potential Revenue scale with mid-market to larger healthcare customers and recent strategic partnerships, combined with substantial funding and a sizable R&D and operations footprint, points to upsell opportunities in high-value diagnostics, companion tests, and service agreements.